July 3, 2025
Correct Billing & Payment for CAR T-Cell & Other Immunotherapy Cases
Effective for inpatient (TOB 11X) claims with discharge dates on or after October 1, 2020:
- MS-DRG 018 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies) assigns to cases that include procedures describing CAR T-cell therapies.
- A payment adjustment applies to clinical trial or expanded access use immunotherapy cases where the CAR T-cell and other immunotherapy product isn’t purchased in the usual manner.
- A payment adjustment doesn’t apply when the CAR T-cell therapy product is purchased in the usual manner, but the case involves a clinical trial of a different product.
Use the billing instructions below to ensure you receive the correct payment.
Clinical Trials
When the CAR T-cell and other immunotherapy product isn’t purchased in the usual manner, report:
- Condition code 30
- Value code D4 and the National Clinical Trial (NCT) number
- Revenue code 0891 or 0892 with a covered token charge ($1.00 or less)
- Diagnosis code Z00.6
The Pricer will apply the payment adjustment.
When the CAR T-cell and other immunotherapy product is purchased in the usual manner, but the case involves a clinical trial of a different product, report:
- Condition code 30
- Value code D4 and the NCT number
- Revenue code 0891 or 0892 with covered charges (greater than $1.00)
- Diagnosis code Z00.6
- Billing Note NTE02 (837I electronic claim) or Remarks (Direct Data Entry (DDE) or paper claim): “Diff Prod Clin Trial”
Important: You must report “Diff Prod Clin Trial” verbatim; the Pricer won’t apply the payment adjustment.
Expanded Access
Report the following:
- Condition code 90
- Revenue code 0891 or 0892 with a covered token charge ($1.00 or less)
- Billing Note NTE02 (837I electronic claim) or Remarks (DDE or paper claim): “Expand Acc Use”
The Pricer will apply the payment adjustment.
Resources
- CR13926
– Fiscal Intermediary Shared System (FISS) Changes to Automate the Application of Condition Code ZC for Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapy Cases Involving a Clinical Trial of a Different Product
- MM12814
– Inpatient & Long-Term Care Hospital Prospective Payment System: FY 2023 Changes
- MM11879
– Fiscal Year (FY) 2021 Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) PPS Changes
- NCD 110.24: CAR T-Cell Therapy Billing Instructions